Domača stranAVDL • NASDAQ
add
Avadel Pharmaceuticals PLC
9,01 $
Po zaprtju:(0,00 %)0,00
9,01 $
Konec trgovanja: 16. maj, 20:00:00 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
8,89 $
Dnevni razpon
8,69 $ - 9,02 $
Letni razpon
6,38 $ - 17,30 $
Tržna kapitalizacija
871,62 mio. USD
Povprečni obseg
1,33 mio.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 52,51 mio. | 93,21 % |
Stroški poslovanja | 49,94 mio. | −3,40 % |
Čisti dohodek | −4,92 mio. | 82,01 % |
Čista dobičkovnost prihodkov | −9,37 | 90,69 % |
Earnings per share | −0,05 | 83,33 % |
EBITDA | −2,18 mio. | 91,46 % |
Efektivna davčna stopnja | −1,61 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 66,48 mio. | −25,12 % |
Skupna sredstva | 167,95 mio. | 0,03 % |
Skupne obveznosti | 93,88 mio. | 4,88 % |
Celoten lastniški kapital | 74,07 mio. | — |
Shares outstanding | 96,74 mio. | — |
Razmerje P/B | 11,55 | — |
Donosnost sredstev | −4,52 % | — |
Donosnost kapitala | −6,61 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −4,92 mio. | 82,01 % |
Denar iz dejavnosti | −8,23 mio. | 72,29 % |
Denar iz naložb | 12,32 mio. | −42,41 % |
Denar iz financiranja | 690,00 tis. | −94,77 % |
Neto sprememba denarnih sredstev | 5,00 mio. | 8,04 % |
Prost denarni tok | −8,71 mio. | 55,25 % |
Vizitka
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
The company was founded as Flamel Technologies SA in Lyon, France in 1990.
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate. Wikipedia
Generalni direktor
Datum ustanovitve
1990
Spletno mesto
Zaposleni
188
